Xeris Biopharma Holdings, Inc.
Company Stats
- Market Cap
- $1.7B
- as of Sep 30, 2026
- Enterprise Value
- $1.9B
- Shares Outstanding
- 182.3M
- Free Float
- 92.6%
Income Statement
- Revenue
- $291.8M
- Operating Income
- $24.9M
- Net Income
- $554,000
- EBITDA
- $26.2M
- Revenue Growth, 3Y
- 38.3%
Balance Sheet
- Cash & Equivalents
- $111.0M
- Total Debt
- $233.6M
- Net Debt
- $122.5M
- Net Debt / EBITDA
- 4.68x
- EV / EBITDA
- 71.18x
- Net Debt / EBIT
- 4.92x
Returns & Capital
- SBC, 3Y Avg
- $17.1M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $291.8M | — | — |
| FY2024 | $203.1M | — | — |
| FY2023 | $163.9M | — | — |
| FY2022 | $110.2M | — | — |
| FY2021 | $49.6M | -$96.6M | -194.8% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 6, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back
AI Infrastructure and Regulatory Risks Scale Across Sectors